Why the study?
Improved cancer survival has increased the recognized incidence of radiation-associated cardiovascular disease, with radiation-associated arrhythmias presenting years or decades following radiotherapy.
Does radiation therapy increase the risk of developing arrhythmias in patients with chest malignancies?
Does radiation therapy increase the risk of developing arrhythmias in patients with chest malignancies?
Effect estimate: HR 1.50 (95% CI null)
p-value: p=0.027
Radiation therapy for chest malignancies is associated with a 2-11% incidence of arrhythmias developing years later, highlighting the need for long-term screening, particularly in patients receiving >30 Gy.
May warrant long-term MACE surveillance after high-dose chest radiation; leaves open prospective confirmation and arrhythmia-specific strategies.
Radiation-associated cardiovascular disease, an increasingly recognised disease process, is a significant adverse effect of radiation therapy for common malignancies that involve the chest, and include lymphomas, lung, mediastinal and breast cancers. Two factors contribute to the increasing incidence of radiation-associated cardiovascular disease: advances in malignancy detection and the improved survival of cancer patients, by which many symptoms of radiation-associated cardiovascular disease, specifically radiation-associated arrhythmias, present years and/or decades following initial radiotherapy. We present a focused overview of the currently understood pathophysiology, prevalence and management strategies of radiation-associated arrhythmias, which include bradyarrhythmias, tachyarrhythmias and autonomic dysfunction.
No takes yet. Share an insight, caveat, or question.
Bedi et al. (2023) conducted a review in Radiation-associated cardiovascular disease. Radiotherapy was evaluated on Major adverse cardiovascular events (HR 1.50, 95% CI null, p=0.027).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: